Learn R Programming

ICsurv (version 1.0.1)

Hemophilia: Hemophilia data

Description

This data were collected as a part of a multi-center prospective study aimed at assessing the HIV-1 infection rate among people with hemophilia. In particular, the individuals in the study were at risk from contracting HIV-1 from blood products made from donor's plasma. In this study, 544 patients were categorized into one of four groups based on their average annual dose of blood products. Specifically, patients were classified into high, medium, low, or no dose group. The goal of the study was to compare the HIV-1 infection rate between these dose groups. The time at which patients contracted HIV-1 is not known exactly, but were known to occur before, between, or after certain observation times. For more details pertaining to this data set see Goedert et al. (1989) and Kroner et al. (1994).

Usage

data(Hemophilia)

Arguments

Format

A data frame with 544 observations on the following 8 variables.

d1

Censoring indicator, 1 if patient's infection time was left censored, 0 otherwise.

d2

Censoring indicator, 1 if patient's infection time was interval censored, 0 otherwise.

d3

Censoring indicator, 1 if patient's infection time was right censored and, otherwise.

L

Left endpoint of the observation interval

R

Right endpoint of the observation interval

Low

Binary variable indicating the patient was a member of the low dose group.

Medium

Binary variable indicating the patient was a member of the medium dose group.

High

Binary variable indicating the patient was a member of the high dose group.

References

Goedert, J., Kessler, C., Adedort, L., Biggar, R., et al., 1989. A progressive-study of human immunodeficiency virus type-1 infection and the development of AIDS in subjects with hemophilia. New England Journal of Medicine 321, 1141-1148.

Kroner, B., Rosenberg, P., Adedort, L., Alvord, W., Goedert, J., 1994. HIV-1 infection incidence among people with hemophilia in the United States and Western Europe, 1978?1990. Journal of Acquired Immune Deficiency Syndromes 7, 279-286.